Plain-English translation of NCT06765980 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing KRIYA-825 (VV-14295), a new gene therapy delivered as a single injection into the eye. The medication is designed to slow the growth of geographic atrophy—a condition where cells in the back of the eye gradually die, causing progressive vision loss. Researchers want to find the safest and most effective dose of this treatment and see whether it can help protect your remaining vision.
Geographic atrophy is a serious, progressive form of age-related macular degeneration that currently has very few treatment options. This trial exists because there is an urgent need for new treatments that can actually slow or stop vision loss in people with this condition, rather than just managing symptoms.
You likely qualify if…
You likely don't qualify if…
You would receive a single injection of the medication into one eye on Day 1 of the study. To manage inflammation, you will take oral steroid pills and use steroid eye drops before and after the injection, gradually transitioning to different eye drops over several weeks. You will then return for multiple follow-up visits over the next year so doctors can monitor your eye health, vision, and any side effects. The entire study participation will last approximately 12 months.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Canada
Israel
New Zealand